News Releases:


miRagen Therapeutics Founders Named to Top Serial Bio Entrepreneurs List

Boulder, Colorado, December 15, 2014 — Genetic Engineering & Biotechnology News today named four miRagen Therapeutics co-founders to its list of Top 17 serial biotech industry entrepreneurs. Included on the list are: William S. (Bill) Marshall, Ph.D., President, CEO... View »

Research Findings Demonstrate miRagen Therapeutic’s Synthetic microRNA-29 Mimic (promiR-29) Reverses Pulmonary Fibrosis

• Findings published from a research collaboration between miRagen Therapeutics. Inc, and Yale University demonstrate that miRagen’s promiR-29 reversed fibrosis in a mouse model of pulmonary fibrosis. • Findings published in the journal EMBO Molecular Medicine. BOULDER, Colo., September... View »

Servier and miRagen Extend Collaboration for the Research, Development and Commercialization of microRNA-targeting Drugs for Cardiovascular Disease

• miRagen and Servier extend their research collaboration by two years to October 2016 to identify and characterize MicroRNA targets and oligonucleotides for cardiovascular diseases. • Servier will continue to fund pre-clinical research and development of microRNA drugs to... View »

miRagen Therapeutics Expands Executive Leadership Team Adding Drug Development Veteran

Dr. David Rodman Joins as Executive Vice President of Research and Development   BOULDER, Colo., March 25, 2014 – miRagen Therapeutics, Inc., a biopharmaceutical company discovering and developing innovative microRNA (miRNA)-targeting therapeutics, today announced the appointment of David Rodman,... View »